Stockreport

VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]

VolitionRX Limited  (VNRX) 
NASDAQ:AMEX Investor Relations: ir.volitionrx.com
PDF Operating Expenses: Reduced by $4.8 million, a 17% decrease compared to 2024. Net Cash Used in Operating Activities: $19.7 million in 2025, down from $25.9 million in [Read more]